NCT00889226 - Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

January 31, 2010

Conditions

Hypercholesterolemia With Type2DM

Interventions

DRUG

Pitavastatin

Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks

DRUG

Atorvastatin

Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks